Recurrence rate and risk factors of recurrent anaphylaxis: A ten-year retrospective cohort study.

IF 1.9 4区 医学 Q3 ALLERGY
Suwannee Uthaisangsook, Nadda Padsee, Sagoontee Inkate
{"title":"Recurrence rate and risk factors of recurrent anaphylaxis: A ten-year retrospective cohort study.","authors":"Suwannee Uthaisangsook, Nadda Padsee, Sagoontee Inkate","doi":"10.12932/AP-130325-2047","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Few studies have investigated the risk factors for recurrent anaphylaxis. Identifying these factors may help patients implement preventive measures.</p><p><strong>Objective: </strong>To determine the rate and risk factors for recurrent anaphylaxis, assess the time to recurrence, and compare the characteristics, triggers, and clinical manifestations between recurrent and non-recurrent cases.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted at Naresuan University Hospital from March 2011 to February 2021, using medical records of patients with ICD-10-confirmed anaphylaxis. Risk factors for recurrence were analyzed using Cox proportional hazards regression model.</p><p><strong>Results: </strong>A total of 439 anaphylactic episodes were identified in 381 patients (49 children, 332 adults). Of these, 42 patients (11.2%) experienced 58 recurrent episodes (7/49 [14.3%] children, 35/332 [10.6%] adults). Food and medications were the most and second most common triggers. The median time to recurrence was 9.9 months (IQR: 3.1-18.8), while the median follow-up duration for non-recurrent cases was 41.8 months (IQR: 23.8-61.8). The recurrent anaphylaxis rate was 4.1 events per 100 person-years. Statistically significant risk factors included a history of food, a history of insect, a history of drug allergies, chest discomfort, and severe anaphylaxis (HR [95%CI]: 3.31 [1.50-7.29], p = 0.003; 4.96 [1.47-16.82], p = 0.010; 5.87 [2.64-13.07], p < 0.001; 2.43 [1.19-4.99], p = 0.015; and 2.29 [1.07-4.88], p = 0.033, respectively). Conversely, palpitations were associated with a lower risk of recurrence (HR 0.11 [0.01-0.86], p = 0.036).</p><p><strong>Conclusions: </strong>Identifying risk factors in anaphylaxis patients enhances medical care and aids in preventing recurrence.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific journal of allergy and immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12932/AP-130325-2047","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Few studies have investigated the risk factors for recurrent anaphylaxis. Identifying these factors may help patients implement preventive measures.

Objective: To determine the rate and risk factors for recurrent anaphylaxis, assess the time to recurrence, and compare the characteristics, triggers, and clinical manifestations between recurrent and non-recurrent cases.

Methods: A retrospective cohort study was conducted at Naresuan University Hospital from March 2011 to February 2021, using medical records of patients with ICD-10-confirmed anaphylaxis. Risk factors for recurrence were analyzed using Cox proportional hazards regression model.

Results: A total of 439 anaphylactic episodes were identified in 381 patients (49 children, 332 adults). Of these, 42 patients (11.2%) experienced 58 recurrent episodes (7/49 [14.3%] children, 35/332 [10.6%] adults). Food and medications were the most and second most common triggers. The median time to recurrence was 9.9 months (IQR: 3.1-18.8), while the median follow-up duration for non-recurrent cases was 41.8 months (IQR: 23.8-61.8). The recurrent anaphylaxis rate was 4.1 events per 100 person-years. Statistically significant risk factors included a history of food, a history of insect, a history of drug allergies, chest discomfort, and severe anaphylaxis (HR [95%CI]: 3.31 [1.50-7.29], p = 0.003; 4.96 [1.47-16.82], p = 0.010; 5.87 [2.64-13.07], p < 0.001; 2.43 [1.19-4.99], p = 0.015; and 2.29 [1.07-4.88], p = 0.033, respectively). Conversely, palpitations were associated with a lower risk of recurrence (HR 0.11 [0.01-0.86], p = 0.036).

Conclusions: Identifying risk factors in anaphylaxis patients enhances medical care and aids in preventing recurrence.

复发性过敏反应的复发率和危险因素:一项十年回顾性队列研究。
背景:很少有研究调查复发性过敏反应的危险因素。识别这些因素可以帮助患者实施预防措施。目的:了解过敏反应再发率及危险因素,评估再发时间,比较复发与非复发病例的特点、触发因素及临床表现。方法:采用2011年3月至2021年2月在那勒山大学附属医院进行的回顾性队列研究,使用icd -10确诊的过敏反应患者的病历。采用Cox比例风险回归模型分析复发危险因素。结果:381例患者(49例儿童,332例成人)共发生439次过敏发作。其中,42例(11.2%)患者复发58次(7/49[14.3%]儿童,35/332[10.6%]成人)。食物和药物是最常见和第二常见的诱因。复发的中位时间为9.9个月(IQR: 3.1-18.8),非复发病例的中位随访时间为41.8个月(IQR: 23.8-61.8)。复发性过敏反应发生率为每100人年4.1次。有统计学意义的危险因素包括食物史、昆虫史、药物过敏史、胸部不适和严重过敏反应(HR [95%CI]: 3.31 [1.50-7.29], p = 0.003;4.96 [1.47-16.82], p = 0.010;5.87 [2.64-13.07], p < 0.001;2.43 [1.19-4.99], p = 0.015;和2.29 [1.07-4.88],p = 0.033)。相反,心悸与较低的复发风险相关(HR 0.11 [0.01-0.86], p = 0.036)。结论:明确过敏反应患者的危险因素,加强医疗护理,有助于预防复发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
12.80
自引率
0.00%
发文量
74
审稿时长
>12 weeks
期刊介绍: The Asian Pacific Journal of Allergy and Immunology (APJAI) is an online open access journal with the recent impact factor (2018) 1.747 APJAI published 4 times per annum (March, June, September, December). Four issues constitute one volume. APJAI publishes original research articles of basic science, clinical science and reviews on various aspects of allergy and immunology. This journal is an official journal of and published by the Allergy, Asthma and Immunology Association, Thailand. The scopes include mechanism, pathogenesis, host-pathogen interaction, host-environment interaction, allergic diseases, immune-mediated diseases, epidemiology, diagnosis, treatment and prevention, immunotherapy, and vaccine. All papers are published in English and are refereed to international standards.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信